Interdependence Public Relations appoints health president
Michael Rinaldo has joined Interdependence Public Relations as president of its global health business. Rinaldo previously led Fleishman Hillard’s global healthcare practice for more than a decade and was general manager at dna Communications.
Fingerpaint promotes two
Nick Bartolomeo has been named head of media and performance marketing and Bryan O’Malley has been named head of technology and performance innovation at Fingerpaint. They will co-lead Fingerpaint’s newly formed SHIFT Performance Center of Excellence.
Syapse names commercial chief
David Pomerantz has been appointed chief commercial officer at Syapse, a real world evidence company. Pomerantz previously spent more than a decade at Kantar Health in various commercial operations positions.
City of Hope names marketing, communications head
Gulden Mesara has joined City of Hope as chief communications and marketing officer. Previously, she was group vice president of communications at Walgreens and has held comms roles with AbbVie and Pfizer.
National Pharmaceutical Council appoints interim CEO
Robert Dubois has been appointed National Pharmaceutical Council’s interim president and CEO. The board of directors will conduct a national search for a permanent replacement for Dan Leonard, who stepped down after more than 12 years as CEO.
Cerner appoints strategy chief
William Mintz has joined healthcare technology company Cerner as chief strategy officer. Previously, Mintz has held strategy roles with Leidos Holdings, Aetna, Care3 and Blue Cross Blue Shield of Massachusetts.
Blueprint Medicines names R&D president
Fouad Namouni has been named president, research and development at Blueprint Medicines. Previously, Namouni was global development lead for Bristol Myers Squibb’s cancer immunotherapy franchise.
Acadia Pharmaceuticals appoints head of R&D
Gudarz Davar has been named EVP and head of research and development at Acadia. Previously, Davar was VP and head of global neurology clinical development at Eli Lilly.
Galectin Therapeutics names CEO
Joel Lewis has been appointed chief executive officer of Galectin Therapeutics. He succeeds Harold Shlevin, who is retiring as CEO but will remain as a scientific and business consultant to Galectin.